Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Nanjing Medical University

Status: Unknown

Conditions: Breast Cancer

Treatments: Drug: Pyrotinib

Study type: Observational

Funder types: Other

Identifiers

NCT04899128

POLAR-01

Details and patient eligibility

About

This is a multicenter, observational, single-arm real world study to evaluate the efficacy and safety of pyrotinib after lapatinib progression.

Full description

HER2-positive breast cancers account for 15%-20% of all breast cancers. The development of HER2 targeted therapies have greatly improved the survival of HER2-positive breast cancer patients. Lapatinib has shown effectiveness in treating HER2-positive metastatic breast cancers, but therapies after lapatinib progression are still controversial. This study is aimed to evaluate the efficacy and safety of pyrotinib after lapatinib progression.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and 18-70 years old
• Metastatic or locally recurrent HER2-positive breast cancer
• Patients received pyrotinib-based therapy after lapatinib failure in treatment for metastasis
• Complete and accurate medical data

Exclusion criteria

• Incomplete medical data

Trial design

100 participants in 1 patient group

Observational Group

Description:

Patients receive pyrotinib-based therapy after lapatinib progression.

Treatment:

Drug: Pyrotinib